A synergistic combination of EHT and caffeine for enhancing PP2A activity to treat neurodegenerative diseases

Background

Lewy body dementias, including Parkinson’s disease (PD) and Dementia with Lewy Bodies (DLB), are progressive neurodegenerative disorders characterized by the accumulation of abnormal protein aggregates in the brain, most notably those containing hyperphosphorylated α-synuclein. These conditions lead to a range of debilitating symptoms, including motor dysfunction, cognitive decline, and neuropsychiatric disturbances. Despite advances in symptomatic treatments, there are currently no disease-modifying therapies that effectively halt or reverse the underlying neurodegenerative processes. The growing prevalence of these disorders, driven by an aging population, underscores the urgent need for novel therapeutic strategies that target the molecular mechanisms responsible for disease progression, particularly those that can prevent or reduce toxic protein aggregation and preserve neuronal function.

Current approaches to treating Lewy body dementias primarily focus on symptomatic relief through dopaminergic medications, cholinesterase inhibitors, and other supportive therapies, but these do not address the root causes of neurodegeneration. Efforts to directly target α-synuclein aggregation or its pathological phosphorylation have faced significant challenges, including limited efficacy, off-target effects, and difficulties in delivering therapeutics across the blood-brain barrier. Moreover, the enzymatic machinery responsible for α-synuclein dephosphorylation, such as protein phosphatase 2A (PP2A), is often dysregulated in affected brains, with reduced activity due to altered post-translational modifications. Existing treatments do not restore this critical phosphatase activity, leaving a key pathogenic process unaddressed. As a result, there remains a substantial unmet need for interventions that can modulate these molecular pathways safely and effectively to achieve neuroprotection and slow disease progression.

Technology

This technology is a novel therapeutic approach for Lewy body dementias, including Parkinson’s disease and Dementia with Lewy Bodies, based on the synergistic combination of eicosanoyl-5-hydroxytryptamide (EHT) and caffeine. EHT, a coffee-derived fatty acid amide, acts as an inhibitor of the enzyme PP2A methylesterase (PME-1), thereby maintaining the phosphatase PP2A in its active, methylated state. Caffeine, an adenosine A2A receptor antagonist, further enhances this effect. Together, these compounds increase PP2A activity, which facilitates the dephosphorylation of α-synuclein at the Ser129 position—a key process in reducing toxic protein aggregates that drive neurodegeneration. The combination has been shown to be effective at subtherapeutic doses and can be delivered via pharmaceutical formulations, dietary supplements, or enriched caffeinated products, resulting in improved motor and cognitive functions in animal models.

What differentiates this technology is its mechanistically validated synergy between EHT and caffeine, targeting a central molecular defect in α-synucleinopathies: the hypomethylation and reduced activity of PP2A. Unlike single-agent therapies, the combined administration of EHT and caffeine restores PP2A methylation and activity, leading to a significant reduction in pathological α-synuclein phosphorylation, preservation of dopaminergic neurons, and reduction of neuroinflammation. The approach is supported by robust experimental evidence in both transgenic and α-synuclein fibril-inoculated mouse models, as well as in vitro studies, demonstrating superior efficacy compared to either agent alone. This dual-compound strategy not only addresses the underlying molecular pathology but also offers practical versatility in product development, ranging from dietary supplements to pharmaceutical drugs, making it a promising and differentiated solution for neurodegenerative diseases.

Benefits

• Synergistic combination of EHT and caffeine enhances PP2A methylation and activity, reducing pathogenic α-synuclein phosphorylation and aggregation.
• Improves motor and cognitive functions in animal models of Lewy body dementias at subtherapeutic doses.
• Preserves dopaminergic neuronal integrity and dopamine levels, mitigating neurodegeneration.
• Reduces neuroinflammation by decreasing microglial and astrocyte activation.
• Can be delivered via dietary supplements, enriched caffeinated products, or pharmaceutical formulations.
• Offers a novel, mechanism-based neuroprotective approach for Parkinson’s disease, Dementia with Lewy Bodies, and potentially other neurodegenerative tauopathies.
• Supported by robust preclinical evidence including behavioral, molecular, and cellular studies.

Applications

• Parkinson’s disease therapeutics
• Dementia with Lewy Bodies treatment
• Neuroprotective dietary supplements
• Enriched caffeinated beverage products
• Alzheimer’s disease adjunct therapy

Additional info

This therapeutic approach utilizes a synergistic combination of eicosanoyl-5-hydroxytryptamide (EHT) and caffeine to treat Lewy body dementias. EHT inhibits PP2A methylesterase, while caffeine acts as an adenosine A2A receptor antagonist. Together, they maintain protein phosphatase 2A in an active methylated state, facilitating α-synuclein dephosphorylation at Ser129. This reduces toxic protein aggregation and neuroinflammation, preserving dopaminergic neuronal integrity and improving cognitive and motor functions.